Harmony Biosciences Holdings (HRMY) - Total Liabilities
Based on the latest financial reports, Harmony Biosciences Holdings (HRMY) has total liabilities worth $373.84 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Harmony Biosciences Holdings (HRMY) investment intensity to see how much of total assets are deployed in long-term investments.
Harmony Biosciences Holdings - Total Liabilities Trend (2018–2025)
This chart illustrates how Harmony Biosciences Holdings's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Harmony Biosciences Holdings balance sheet assets.
Harmony Biosciences Holdings Competitors by Total Liabilities
The table below lists competitors of Harmony Biosciences Holdings ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Haemonetics Corporation
NYSE:HAE
|
USA | $1.60 Billion |
|
Legend Holdings Corporation
F:1PC
|
Germany | €665.71 Billion |
|
Inari Amertron Bhd
KLSE:0166
|
Malaysia | RM308.02 Million |
|
Tecnicas Reunidas
MC:TRE
|
Spain | €5.23 Billion |
|
Winner Medical Co Ltd
SHE:300888
|
China | CN¥5.93 Billion |
|
Voltronic Power Technology Corp
TW:6409
|
Taiwan | NT$7.46 Billion |
|
Sixt SE
XETRA:SIX2
|
Germany | €5.15 Billion |
|
El Al Israel Airlines Ltd
TA:ELAL
|
Israel | ILA3.81 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Harmony Biosciences Holdings's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Harmony Biosciences Holdings to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Harmony Biosciences Holdings's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Harmony Biosciences Holdings (2018–2025)
The table below shows the annual total liabilities of Harmony Biosciences Holdings from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $401.41 Million | +18.05% |
| 2024-12-31 | $340.05 Million | -1.28% |
| 2023-12-31 | $344.46 Million | +27.09% |
| 2022-12-31 | $271.03 Million | +9.76% |
| 2021-12-31 | $246.94 Million | -25.15% |
| 2020-12-31 | $329.89 Million | +178.89% |
| 2019-12-31 | $118.29 Million | +1425.51% |
| 2018-12-31 | $7.75 Million | -- |
About Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that … Read more